Northislet
Jan Inghes Torg 28, Stockholm, SE-12071, Sweden
Overview
Northislet is a Nordic growth investor focused on investments in technology and life sciences. Northislet invests significantly in tiny growing enterprises where active ownership can increase long-term value. They select early-stage Tech and Life Science firms and use an active strategy, leveraging our skills and network, to assist in increasing the total value of our investments.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Investment portfolio
- BioLamina
Participated · Equity · Sep 2023
Founded in 2009 by Dr Karl Tryggvason and Kristian Tryggvason, BioLamina produces full-length, chemically defined, animal origin-free human recombinant laminins (Biolaminin®) used to support controlled cell culture systems. Its substrates are designed to enable reliable growth and differentiation of pluripotent stem cells and other primary cells and are used in cell therapy development, including phase I–III clinical trials. The company emphasizes scalable, high-quality cell culture solutions to improve consistency for cell therapies and drug testing. BioLamina recently secured a €20 million venture debt loan from the European Investment Bank to expand manufacturing capacity, optimise processes, broaden its product portfolio and strengthen its technological base. The financing is intended to extend the company’s funding runway while minimising immediate equity dilution.
Team
No current team members are available.